NCT07462650 is a Phase 1, PHASE2 clinical trial of EB-DUO-CAR-NK-CEA/GCC (IV) in Colorectal Cancer Metastatic, sponsored by Beijing Biotech.

Who is sponsoring NCT07462650?

NCT07462650 is sponsored by Beijing Biotech.

What drugs are being tested in NCT07462650?

Interventions in NCT07462650: EB-DUO-CAR-NK-CEA/GCC (IV).

What condition does NCT07462650 study?

NCT07462650 studies Colorectal Cancer Metastatic, Adenocarcinoma of Colon.

Is NCT07462650 still recruiting?

NCT07462650 is currently recruiting now. Last updated 10 March 2026.

Last reviewed 2026-03-10 · How we verify

NCT07462650

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Recruiting now Phase 1, PHASE2 Last updated 10 March 2026

What this trial tests

Phase 1, PHASE2 trial testing EB-DUO-CAR-NK-CEA/GCC (IV) in Colorectal Cancer Metastatic in 48 participants. Currently enrolling.

Timeline

1 February 2026

Primary endpoint
21 December 2027

22 December 2028

Quick facts

Lead sponsor	Beijing Biotech
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	1 February 2026
Primary completion	21 December 2027
Estimated completion	22 December 2028
Sites	1 location across China

Drugs / interventions tested

EB-DUO-CAR-NK-CEA/GCC (IV) — full drug profile →

Conditions studied

Colorectal Cancer Metastatic — all drugs for Colorectal Cancer Metastatic →
Adenocarcinoma of Colon — all drugs for Adenocarcinoma of Colon →

Sponsor

Beijing Biotech — full company profile →

Who can join

Adults 18 to 75, any sex, with Colorectal Cancer Metastatic or Adenocarcinoma of Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Cancer Metastatic

Currently open trials in the same condition.

NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
NCT07172282 — INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases · EARLY_PHASE1 · recruiting
NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting
NCT06698146 — Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection · recruiting

Other Beijing Biotech trials

Trials by the same sponsor.

NCT07523529 — Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07510815 — Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma · Phase 1, PHASE2 · recruiting
NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07462650 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Biotech
Last refreshed: 10 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07462650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing